Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Limited readies to reveal clinical data

Actinogen Limited readies to reveal clinical data

Actinogen Limited (ASX:ACW) has been granted a trading halt by the ASX pending the results of the CSF clinical data.

The company is focussed on the treatment of Alzheimer’s disease and mild cognitive impairment.

The halt will remain in place until the opening of trade on Wednesday 30th September 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
scientist with vial
17:20
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use